ReviewJournal of virology2026
Roles of the cGAS-STING signaling pathway in viral latency.
Review in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The cGAS-STING/MITA pathway in innate antiviral immunity and beyond.Cell insight · 2026Review
- Macrophages in oncoviral infections: from immune regulators to therapeutic targets.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Viral latency is a sophisticated survival strategy that allows the viral genome to persist indefinitely while remaining invisible to immune surveillance. This stealth impedes eradication, and episodic reactivation compounds the hurdle, necessitating therapeutic innovation. Recently, increasing evidence has indicated that the cGAS-STING pathway, which senses nonself or damaged DNA, plays vital roles in the establishment, maintenance, and reversal of latency in a subset of viruses. Given its central role in triggering innate immune responses, the cGAS-STING pathway has emerged as a high-priority target for therapeutic intervention. Here, we outline the multilayered arms race between latent viruses and the cGAS-STING pathway. Latent viruses generally conceal their genomes from cGAS, disrupt cGAS-STING signaling to limit innate immune responses, and subsequently deploy latency-associated factors to maintain pathway silencing and evade immune surveillance. We also elucidated the paradoxical engagement of cGAS-STING during reactivation. Motivated by encouraging preclinical data on STING agonists and the central role of the STING signaling pathway in cell fate decisions, we synthesized the current knowledge and proposed targeting this pathway for therapeutic intervention to reduce viral latency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.